Ziqiang Yan

Ziqiang Yan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LWLinbang Wang
Linbang Wang
YLYu Liu
Yu Liu
JTJiaojiao Tai
Jiaojiao Tai
XDXinyu Dou
Xinyu Dou
HYHongjuan Yang
Hongjuan Yang
XLXiaoguang Liu
Xiaoguang Liu
Osteosarcoma (OS) is the most common malignant bone tumor with high pathological heterogeneity. Our study aimed to investigate disulfidptosis-related modification patterns in OS and their relationship with survival outcomes in patients with OS. We analyzed the single-cell-level expression profiles of disulfidptosis-related genes (DSRGs) in both OS microenvironment and OS subclusters, and HMGB1 was found to be crucial for intercellular regulation of OS disulfidptosis. Next, we explored the molecular clusters of OS based on DSRGs and related immune cell infiltration using transcriptome data. Subsequently, the hub genes of disulfidptosis in OS were screened by applying multiple machine models. In vitro and patient experiments validated our results. Three main disulfidptosis-related molecular clusters were defined in OS, and immune infiltration analysis suggested high immune heterogeneity between distinct clusters. The in vitro experiment confirmed decreased cell viability of OS after ACTB silencing and higher expression of ACTB in patients with lower immune scores. Our study systematically revealed the underlying relationship between disulfidptosis and OS at the single-cell level, identified disulfidptosis-related subtypes, and revealed the potential role of ACTB expression in OS disulfidptosis.

25 October 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
JTJiaojiao Tai
Jiaojiao Tai
LWLinbang Wang
Linbang Wang
ZYZiqiang Yan
Ziqiang Yan
JLJingkun liu
Jingkun liu
Background: Rheumatoid arthritis (RA) is a disabling autoimmune disease that affects multiple joints. Accumulating evidence suggests that imbalances in liquid–liquid phase separation (LLPS) can lead to altered spatiotemporal coordination of biomolecular condensates, which play important roles in carcinogenesis and inflammatory diseases. However, the role of LLPS in the development and progression of RA remains unclear.Methods: We screened RA and normal samples from GSE12021, GSE55235, and GSE55457 transcriptome datasets and GSE129087 and GSE109449 single-cell sequencing datasets from Gene Expression Omnibus database to investigate the pathogenesis of LLPS-related hub genes at the transcriptome and single cell sequencing levels. Machine learning algorithms and weighted gene co-expression network analysis were applied to screen hub genes, and hub genes were validated using correlation studies.Results: Differential analysis showed that 36 LLPS-related genes were significantly differentially expressed in RA, further random forest and support vector machine identified four and six LLPS-related genes, respectively, and weighted gene co-expression network analysis identified 396 modular genes. Hybridization of the three sets revealed two hub genes, MYC and MAP1LC3B, with AUCs of 0.907 and 0.911, respectively. Further ROC analysis of the hub genes in the GSE55457 dataset showed that the AUCs of MYC and MAP1LC3B were 0.815 and 0.785, respectively. qRT-PCR showed that the expression of MYC and MAP1LC3B in RA synovial tissues was significantly lower than that in the normal control synovial tissues. Correlation analysis between hub genes and the immune microenvironment and single-cell sequencing analysis revealed that both MYC and MAP1LC3B were significantly correlated with the degree of infiltration of various innate and acquired immune cells.Conclusion: Our study reveals a possible mechanism for LLPS in RA pathogenesis and suggests that MYC and MAP1LC3B may be potential novel molecular markers for RA with immunological significance.

29 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JTJiaojiao Tai
Jiaojiao Tai
LWLinbang Wang
Linbang Wang
YXYijun Xie
Yijun Xie
YLYang Li
Yang Li
HFHua Fu
Hua Fu
JLJingkun liu
Jingkun liu
Machine learning technology has been extensively applied in the medical field, particularly in the context of disease prediction and patient rehabilitation assessment. Acute spinal cord injury (ASCI) is a sudden trauma that frequently results in severe neurological deficits and a significant decline in quality of life. Early prediction of neurological recovery is crucial for the personalized treatment planning. While extensively explored in other medical fields, this study is the first to apply multiple machine learning methods and Shapley Additive Explanations (SHAP) analysis specifically to ASCI for predicting neurological recovery. A total of 387 ASCI patients were included, with clinical, imaging, and laboratory data collected. Key features were selected using univariate analysis, Lasso regression, and other feature selection techniques, integrating clinical, radiomics, and laboratory data. A range of machine learning models, including XGBoost, Logistic Regression, KNN, SVM, Decision Tree, Random Forest, LightGBM, ExtraTrees, Gradient Boosting, and Gaussian Naive Bayes, were evaluated, with Gaussian Naive Bayes exhibiting the best performance. Radiomics features extracted from T2-weighted fat-suppressed MRI scans, such as original_glszm_SizeZoneNonUniformity and wavelet-HLL_glcm_SumEntropy, significantly enhanced predictive accuracy. SHAP analysis identified critical clinical features, including IMLL, INR, BMI, Cys C, and RDW-CV, in the predictive model. The model was validated and demonstrated excellent performance across multiple metrics. The clinical utility and interpretability of the model were further enhanced through the application of patient clustering and nomogram analysis. This model has the potential to serve as a reliable tool for clinicians in the formulation of personalized treatment plans and prognosis assessment.

24 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JTJiaojiao Tai
Jiaojiao Tai
LWLinbang Wang
Linbang Wang
HGHao Guo
Hao Guo
ZYZiqiang Yan
Ziqiang Yan
JLJingkun liu
Jingkun liu
The significance of N6-methyladenosine (m6A) RNA modifications in the progression of breast cancer (BC) has been recognised. However, their potential role and mechanism of action in the tumour microenvironment (TME) and immune response has not been demonstrated. Thus, the role of m6A regulators and their downstream target gene components in BC remain to be explored. In this study, we used a series of bioinformatics methods and experiments to conduct exploratory research on the possible role of m6A regulators in BC. First, two regulatory modes of immune activation and inactivation were determined by tumour classification. The TME, immune cell infiltration, and gene set variation analysis results confirmed the reliability of this pattern. The prognostic model of the m6A regulator was established by the least absolute shrinkage and selection operator and univariate and multivariate Cox analyses, with the two regulators most closely related to survival verified by real-time quantitative reverse transcription polymerase chain reaction. Next, the prognostic m6A regulator identified in the model was crossed with the differential copy number of variant genes in invasive BC (IBC), and it was determined that YTHDF1 was a hub regulator. Subsequently, single-cell analysis revealed the expression patterns of m6A regulators in different IBC cell populations and found that YTHDF1 had significantly higher expression in immune-related IBC cells. Therefore, we selected the intersection of the BC differential expression gene set and the differential expression gene set of a cell line with knocked-down YTHDF1 in literature to identify downstream target genes of YTHDF1, in which we found IFI6, EIR, and SPTBN1. A polymerase chain reaction was conducted to verify the results. Finally, we confirmed the role of YTHDF1 as a potential prognostic biomarker through pan-cancer analysis. Furthermore, our findings revealed that YTHDF1 can serve as a new molecular marker for BC immunotherapy.

30 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JTJiaojiao Tai
Jiaojiao Tai
LWLinbang Wang
Linbang Wang
YLYang Li
Yang Li
MCMingxin Chen
Mingxin Chen
ZYZiqiang Yan
Ziqiang Yan
JLJingkun liu
Jingkun liu
Acute kidney injury is a common and severe complication following total hip arthroplasty, particularly in elderly or high-risk patients with chronic conditions, significantly increasing morbidity and mortality rates. Traditional prediction methods often struggle with the complexity of multidimensional healthcare data. To address this, we developed a machine learning-based prediction model using multidimensional data from 4601 total hip arthroplasty patients, encompassing 16 general variables (e.g., demographic characteristics, surgical duration, and hospital stay) and 53 laboratory indicators (e.g., Cystatin C, D-dimer, and glucose). Feature selection was performed using Random Forest, Lasso regression, and mutual information analysis, with clinically relevant features such as Cystatin C, glucose, and N-terminal proBNP retained to enhance model interpretability and predictive power. To address class imbalance, we applied the Synthetic Minority Over-sampling Technique and Edited Nearest Neighbors. Among multiple models, CatBoost achieved the best performance, with an area under the receiver operating characteristic curve of 0.95 (95% CI 0.93–0.96), an accuracy of 0.88 (95% CI 0.85–0.90), and an F1-score of 0.79 (95% CI 0.75–0.84) in the internal validation set. External validation using an independent hospital dataset (n = 240) further confirmed the model’s robustness, with an AUC of 0.65 (95% CI 0.57–0.73). However, the substantial performance decline in external validation underscores the need for cautious interpretation of performance metrics and institution-specific validation prior to clinical deployment. Shapley Additive Explanations analysis identified Cystatin C, surgical duration, and creatinine as key predictors, demonstrating the model’s transparency and clinical relevance. A real-time prediction system, developed using the Flask framework, was validated externally, confirming its utility for acute kidney injury risk assessment and personalized postoperative management. These findings highlight the model’s potential to improve clinical decision-making and outcomes for high-risk patients undergoing total hip arthroplasty.

30 August 2025 in Materials Today Bio
Verified
Journal Article
Open access
LWLinbang Wang
Linbang Wang
YLYu Liu
Yu Liu
ZWZiyu Wang
Ziyu Wang
JLJingkun Liu
Jingkun Liu
ZYZiqiang Yan
Ziqiang Yan
XLXiaoguang Liu
Xiaoguang Liu
Although immunotherapy exhibits remarkable clinical potential for the treatment of tumors, immune responses generated by conventional approaches often fail to completely eradicate osteosarcoma. This inadequacy stems primarily from the low immunogenicity of osteosarcoma-derived neoantigens and the limitations of conventional strategies that focus on enhancing only a single step in the tumor immunity cycle and fail to effectively drive a comprehensive immune response. To address these challenges and augment antitumor immune responses, we developed the innovative core-shell nanoparticle system BaTiO3-indisulam@PD1-cell Membrane Nanoparticles (BI@PCM NPs). This system achieves tumor targeting and enables the ultrasound-triggered controlled release of components. Unlike traditional methods that rely on DNA damage-mediated neoantigen production, BI@PCM disrupts alternative RNA splicing, thereby generating high-quality Endogenous Tumor Neoantigens (ETNs). These ETNs are dynamically transported from the tumor site to lymph nodes (LNs) using BaTiO3 nanocubes (≈10 nm) as efficient nanocarriers. BaTiO3 acts as a piezoelectric catalyst, producing reactive oxygen species (ROS) upon ultrasound stimulation, further enhancing the immunogenic death of osteosarcoma cells. Integration of Pd1 cell membrane coating provides enhanced targeting capabilities and significantly amplifies cytotoxic T-cell activation. By strengthening multiple immune cycle steps, BI@PCM exhibits immense potential to revolutionize personalized tumor immunotherapy and provide a robust solution for osteosarcoma treatment.